Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

9-8471 (international).

A replay of the call will be available from 12:00 p.m. ET on March 31, 2008 until April 14, 2008 at midnight. To access the replay, please dial 1- 877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 279686. A live audio webcast of the call will also be available on the Investors section on the corporate web site at http://www.sinovac.com. A webcast replay can be accessed on the corporate website beginning March 31, 2008 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B) and Anflu(R) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements in
'/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ ... CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, ... of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/29/2015)... ... 2015 , ... Asymmetrex, LLC founder and director ... full range of capabilities of its unique cache of technologies for identifying, quantifying, ... renewal and repair of normal tissues and organs. This property makes them the ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... can be avoidedATLANTA, Jan. 30 For the many women ... help after this week,s birth of octuplets in California, ... be prevented with today,s advanced technologies."Infertility affects 7.3 million ... be pregnant to do is shy away from infertility ...
... In the electronics industry, thin metal films are deposited ... ions atoms with a positive charge to knock ... Department of Energy,s Lawrence Berkeley National Laboratory have now developed ... high-quality metal films in complex, three-dimensional nanoscale patterns at a ...
... NKTR ) announced today that Irwin Lerner has ... Mr. Lerner, former Chairman of,Hoffmann-La Roche Inc., has been a ... is retiring due to personal reasons. , ... acknowledge the,contributions that Mr. Lerner has made by providing the ...
Cached Biology Technology:You Want To Have a Baby...But Not Eight 2A supercharged metal-ion generator 2A supercharged metal-ion generator 3A supercharged metal-ion generator 4A supercharged metal-ion generator 5
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... When a person develops a sore or a boil, it ... infection. Then it resolves and flattens into the skin, often ... scenario plays out in the blood vessels. However, when there ... of blood vessels to recover from inflammation atherosclerosis or ...
... you eat right and exercise regularly, chances are high that ... thanks to new findings by researchers from Harvard and Baylor, ... studies recently published online in The FASEB Journal ... have the potential to save millions of lives. Both ...
... The Stowers Institute,s Shilatifard Lab has identified a new role ... polymerase II (Pol II) the enzyme that synthesizes ... protein-synthesizing machinery of the cell. Precise control of the ... essential for development. In a paper published online in the ...
Cached Biology News:Failure to bridle inflammation spurs atherosclerosis 2New discoveries from Harvard and Baylor get to the heart of cardiovascular disease 2New discoveries from Harvard and Baylor get to the heart of cardiovascular disease 3